{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T21:23:01Z","timestamp":1773177781234,"version":"3.50.1"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005322","name":"Recep Tayyip Erdo\u011fan University","doi-asserted-by":"publisher","award":["TTU-2020-1138"],"award-info":[{"award-number":["TTU-2020-1138"]}],"id":[{"id":"10.13039\/501100005322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Diagnostic Pathology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.anndiagpath.2024.152380","type":"journal-article","created":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T06:12:23Z","timestamp":1728540743000},"page":"152380","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Prognostic impact of EGFR expression and immunohistochemistry-based \u201cmolecular classification\u201d in bladder cancer"],"prefix":"10.1016","volume":"73","author":[{"given":"Yusuf Onder","family":"Ozsagir","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elif","family":"Ozsagir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eyup","family":"Dil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huseyin","family":"Eren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sevdegul","family":"Aydin Mungan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Recep","family":"Bedir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.anndiagpath.2024.152380_bb0005","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1016\/j.clgc.2014.07.010","article-title":"Molecular profiling of infiltrating urothelial carcinoma of bladder and nonbladder origin","volume":"13","author":"Millis","year":"2015","journal-title":"Clin Genitourin Cancer"},{"issue":"3","key":"10.1016\/j.anndiagpath.2024.152380_bb0010","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.ajpath.2013.05.013","article-title":"Toward a molecular pathologic classification of urothelial carcinoma","volume":"183","author":"Sj\u00f6dahl","year":"2013","journal-title":"Am J Pathol"},{"issue":"7492","key":"10.1016\/j.anndiagpath.2024.152380_bb0015","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature12965","article-title":"Comprehensive molecular characterization of urothelial bladder carcinoma","volume":"507","author":"Weinstein","year":"2014","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.anndiagpath.2024.152380_bb0020","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1369\/00221554221095530","article-title":"Immunohistochemical assays for bladder cancer molecular subtyping: optimizing parsimony and performance of Lund taxonomy classifiers","volume":"70","author":"Hardy","year":"2022","journal-title":"J Histochem Cytochem"},{"key":"10.1016\/j.anndiagpath.2024.152380_bb0025","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ebiom.2016.08.036","article-title":"Meta-analysis of the luminal and basal subtypes of bladder cancer and the identification of signature immunohistochemical markers for clinical use","volume":"12","author":"Dadhania","year":"2016","journal-title":"EBioMedicine"},{"key":"10.1016\/j.anndiagpath.2024.152380_bb0030","doi-asserted-by":"crossref","first-page":"7178","DOI":"10.12659\/MSM.911640","article-title":"Overexpression of epidermal growth factor receptor (EGFR) and HER-2 in bladder carcinoma and its association with patients\u2019 clinical features","volume":"24","author":"Li","year":"2018","journal-title":"Med Sci Monit"},{"issue":"1","key":"10.1016\/j.anndiagpath.2024.152380_bb0035","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3233\/BLC-150037","article-title":"Bladder cancer molecular taxonomy: summary from a consensus meeting","volume":"2","author":"Lerner","year":"2016","journal-title":"Bladder Cancer"},{"issue":"4","key":"10.1016\/j.anndiagpath.2024.152380_bb0040","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.ajur.2016.09.009","article-title":"Intrinsic subtypes and bladder cancer metastasis","volume":"3","author":"McConkey","year":"2016","journal-title":"Asian J Urol"},{"issue":"1","key":"10.1016\/j.anndiagpath.2024.152380_bb0045","doi-asserted-by":"crossref","first-page":"4858","DOI":"10.1038\/s41467-020-18640-0","article-title":"Molecular correlates of cisplatin-based chemotherapy response in muscle invasive bladder cancer by integrated multi-omics analysis","volume":"11","author":"Taber","year":"2020","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.anndiagpath.2024.152380_bb0050","doi-asserted-by":"crossref","first-page":"9743","DOI":"10.1038\/s41598-020-66747-7","article-title":"Assessment of luminal and basal phenotypes in bladder cancer","volume":"10","author":"Guo","year":"2020","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.anndiagpath.2024.152380_bb0055","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/path.4886","article-title":"Molecular classification of urothelial carcinoma: global mRNA classification versus tumour-cell phenotype classification","volume":"242","author":"Sj\u00f6dahl","year":"2017","journal-title":"J Pathol"},{"issue":"3","key":"10.1016\/j.anndiagpath.2024.152380_bb0060","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/path.5318","article-title":"Molecular pathology of the luminal class of urothelial tumors","volume":"249","author":"Bernardo","year":"2019","journal-title":"J Pathol"},{"issue":"6","key":"10.1016\/j.anndiagpath.2024.152380_bb0065","doi-asserted-by":"crossref","first-page":"695","DOI":"10.5858\/arpa.2018-0329-RA","article-title":"Bladder cancer in the genomic era","volume":"143","author":"Guo","year":"2019","journal-title":"Arch Pathol Lab Med"},{"issue":"1","key":"10.1016\/j.anndiagpath.2024.152380_bb0070","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12894-018-0373-0","article-title":"Prognostic significance of epidermal growth factor receptor (EGFR) over expression in urothelial carcinoma of urinary bladder","volume":"18","author":"Hashmi","year":"2018","journal-title":"BMC Urol"},{"issue":"4","key":"10.1016\/j.anndiagpath.2024.152380_bb0075","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1159\/000447140","article-title":"Expression of epidermal growth factor receptor and transforming growth factor alpha in cancer bladder: schistosomal and non-schistosomal","volume":"9","author":"Badawy","year":"2017","journal-title":"Curr Urol"},{"issue":"10","key":"10.1016\/j.anndiagpath.2024.152380_bb0080","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/j.humpath.2011.11.016","article-title":"High epidermal growth factor receptor immunohistochemical expression in urothelial carcinoma of the bladder is not associated with EGFR mutations in exons 19 and 21: a study using formalin-fixed, paraffin-embedded archival tissues","volume":"43","author":"Chaux","year":"2012","journal-title":"Hum Pathol"},{"issue":"5","key":"10.1016\/j.anndiagpath.2024.152380_bb0085","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/path.5230","article-title":"Molecular profiling in muscle-invasive bladder cancer: more than the sum of its parts","volume":"247","author":"Sj\u00f6dahl","year":"2019","journal-title":"J Pathol"},{"issue":"4","key":"10.1016\/j.anndiagpath.2024.152380_bb0090","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","article-title":"A consensus molecular classification of muscle-invasive bladder cancer","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur Urol"},{"issue":"10","key":"10.1016\/j.anndiagpath.2024.152380_bb0095","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s11912-018-0727-5","article-title":"Molecular subtypes of bladder cancer","volume":"20","author":"McConkey","year":"2018","journal-title":"Curr Oncol Rep"},{"issue":"3","key":"10.1016\/j.anndiagpath.2024.152380_bb0100","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive molecular characterization of muscle-invasive bladder cancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.anndiagpath.2024.152380_bb0105","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13000-023-01295-y","article-title":"Immunohistochemical based molecular subtypes of muscle-invasive bladder cancer: association with HER2 and EGFR alterations, neoadjuvant chemotherapy response and survival","volume":"18","author":"Helal","year":"2023","journal-title":"Diagn Pathol"},{"issue":"6","key":"10.1016\/j.anndiagpath.2024.152380_bb0110","first-page":"968","article-title":"Molecular classification of muscle-invasive bladder cancer based on a simplified immunohistochemical panel using GATA3, CK5\/6 and p16","volume":"23","author":"Terlevi\u0107","year":"2023","journal-title":"Biomol Biomed"},{"issue":"4","key":"10.1016\/j.anndiagpath.2024.152380_bb0115","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s00428-020-02951-0","article-title":"A four-antibody immunohistochemical panel can distinguish clinico-pathological clusters of urothelial carcinoma and reveals high concordance between primary tumor and lymph node metastases","volume":"478","author":"Bontoux","year":"2021","journal-title":"Virchows Arch"},{"issue":"6","key":"10.1016\/j.anndiagpath.2024.152380_bb0120","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s10552-017-0885-z","article-title":"Age at diagnosis, obesity, smoking, and molecular subtypes in muscle-invasive bladder cancer","volume":"28","author":"Sun","year":"2017","journal-title":"Cancer Causes Control"},{"issue":"1","key":"10.1016\/j.anndiagpath.2024.152380_bb0125","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1038\/s41467-021-22465-w","article-title":"An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer","volume":"12","author":"Lindskrog","year":"2021","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.anndiagpath.2024.152380_bb0130","doi-asserted-by":"crossref","first-page":"75","DOI":"10.21873\/invivo.12234","article-title":"Contemporary molecular classification of urinary bladder cancer","volume":"35","author":"Goutas","year":"2021","journal-title":"In Vivo"},{"issue":"2","key":"10.1016\/j.anndiagpath.2024.152380_bb0135","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/cjp2.245","article-title":"Diagnostic and prognostic implications of a three-antibody molecular subtyping algorithm for non-muscle invasive bladder cancer","volume":"8","author":"Jackson","year":"2022","journal-title":"J Pathol Clin Res"},{"key":"10.1016\/j.anndiagpath.2024.152380_bb0140","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3389\/fonc.2020.00102","article-title":"Traditional classification and novel subtyping systems for bladder cancer","volume":"10","author":"Zhu","year":"2020","journal-title":"Front Oncol"},{"issue":"14","key":"10.1016\/j.anndiagpath.2024.152380_bb0145","doi-asserted-by":"crossref","first-page":"7819","DOI":"10.3390\/ijms23147819","article-title":"Are we ready to implement molecular subtyping of bladder cancer in clinical practice? Part 1: general issues and marker expression","volume":"23","author":"Sanguedolce","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.anndiagpath.2024.152380_bb0150","doi-asserted-by":"crossref","DOI":"10.6061\/clinics\/2021\/e2587","article-title":"Combined use of immunohistochemical markers of basal and luminal subtypes in urothelial carcinoma of the bladder: association with clinicopathological features and outcomes","volume":"76","author":"Ravanini","year":"2021","journal-title":"Clinics"},{"issue":"3","key":"10.1016\/j.anndiagpath.2024.152380_bb0155","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.eururo.2018.08.027","article-title":"Molecular subtypes of urothelial bladder cancer: results from a meta-cohort analysis of 2411 tumors","volume":"75","author":"Tan","year":"2019","journal-title":"Eur Urol"},{"issue":"244","key":"10.1016\/j.anndiagpath.2024.152380_bb0160","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008970","article-title":"EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype","volume":"6","author":"Rebouissou","year":"2014","journal-title":"Sci Transl Med"},{"issue":"5","key":"10.1016\/j.anndiagpath.2024.152380_bb0165","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/MOU.0000000000000200","article-title":"Genetic subtypes of invasive bladder cancer","volume":"25","author":"McConkey","year":"2015","journal-title":"Curr Opin Urol"},{"issue":"16","key":"10.1016\/j.anndiagpath.2024.152380_bb0170","doi-asserted-by":"crossref","first-page":"5670","DOI":"10.3390\/ijms21165670","article-title":"Evolution of urothelial bladder cancer in the context of molecular classifications","volume":"21","author":"Minoli","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"12","key":"10.1016\/j.anndiagpath.2024.152380_bb0175","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1158\/1078-0432.CCR-12-0077-T","article-title":"A molecular taxonomy for urothelial carcinoma","volume":"18","author":"Sj\u00f6dahl","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.anndiagpath.2024.152380_bb0180","article-title":"CK5\/6 and GATA3 defined phenotypes of muscle-invasive bladder cancer: impact in adjuvant chemotherapy and molecular subtyping of negative cases","volume":"16","author":"Koll","year":"2022","journal-title":"Front Med"},{"issue":"10","key":"10.1016\/j.anndiagpath.2024.152380_bb0185","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.urolonc.2019.04.010","article-title":"Molecular subtypes applied to a population-based modern cystectomy series do not predict cancer-specific survival","volume":"37","author":"Kollberg","year":"2019","journal-title":"Urologic Oncology: Seminars and Original Investigations"},{"key":"10.1016\/j.anndiagpath.2024.152380_bb0190","doi-asserted-by":"crossref","first-page":"4011","DOI":"10.1007\/s00345-021-03788-1","article-title":"Prognostic impact of molecular muscle-invasive bladder cancer subtyping approaches and correlations with variant histology in a population-based mono-institutional cystectomy cohort","volume":"39","author":"Weyerer","year":"2021","journal-title":"World J Urol"}],"container-title":["Annals of Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1092913424001175?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1092913424001175?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T06:29:53Z","timestamp":1731652193000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1092913424001175"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":38,"alternative-id":["S1092913424001175"],"URL":"https:\/\/doi.org\/10.1016\/j.anndiagpath.2024.152380","relation":{},"ISSN":["1092-9134"],"issn-type":[{"value":"1092-9134","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic impact of EGFR expression and immunohistochemistry-based \u201cmolecular classification\u201d in bladder cancer","name":"articletitle","label":"Article Title"},{"value":"Annals of Diagnostic Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anndiagpath.2024.152380","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"152380"}}